Revefenacin

From WikiProjectMed
Jump to navigation Jump to search
Revefenacin
Revefenacin.svg
Names
Trade namesYupelri
Clinical data
Drug classLong-acting muscarinic antagonist (LAMA)[1]
Main usesChronic obstructive pulmonary disease (COPD)[1]
Side effectsCough, upper respiratory tract infection, headache, back pain[2]
Pregnancy
category
  • US: N (Not classified yet)
Routes of
use
Inhalation
Typical dose175 ucg (3 mL) OD[2]
External links
AHFS/Drugs.comMonograph
US NLMRevefenacin
MedlinePlusa619009
Legal
Legal status
Chemical and physical data
FormulaC35H43N5O4
Molar mass597.760 g·mol−1
3D model (JSmol)
  • CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N
  • InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)
  • Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N

Revefenacin, sold under the brand name Yupelri, is a medication used for the long term treat of chronic obstructive pulmonary disease (COPD).[1] It is used by breathing it into the lungs.[1]

Common side effects include cough, upper respiratory tract infection, headache, and back pain.[2] Other side effects may include allergic reactions, bronchospasm, and urinary retention.[1] It is a long-acting muscarinic antagonist (LAMA).[1]

Revefenacin was approved for medical use in the United States in 2018.[1] It is not available in the United Kingdom or Europe as of 2021.[3] In the United States it costs about 1,100 USD per month.[4]

Medical uses

Dosage

It is taken at a dose of 175 mcg (3 mL) once per day.[2]

History

It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.[5]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Revefenacin Monograph for Professionals". Drugs.com. Archived from the original on 17 April 2021. Retrieved 16 October 2021.
  2. 2.0 2.1 2.2 2.3 "DailyMed - YUPELRI- revefenacin solution". dailymed.nlm.nih.gov. Archived from the original on 4 August 2020. Retrieved 17 October 2021.
  3. "Revefenacin". SPS - Specialist Pharmacy Service. 28 December 2015. Archived from the original on 17 October 2021. Retrieved 17 October 2021.
  4. "Yupelri Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 17 October 2021.
  5. Heo YA (January 2019). "Revefenacin: First Global Approval". Drugs. 79 (1): 85–91. doi:10.1007/s40265-018-1036-x. PMC 6445810. PMID 30560478.

External links

External sites:
Identifiers: